Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CorMedix Inc (CRMD : NSDQ)

• Company Description    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $11.71 Daily Weekly Monthly 20 Day Moving Average: 2,147,341 shares Shares Outstanding: 67.82 (millions) Market Capitalization: $794.23 (millions) Beta: 1.58 52 Week High: $17.43 52 Week Low: $3.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.20% -24.15% 12 Week 52.67% 28.42% Year To Date 44.57% 35.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 300 CONNELL DRIVE SUITE 4200 - BERKELEY HEIGHTS,NJ 07922 USA ph: 908-517-9500 fax: 908-429-4307 daniel@lifesciadvisors.com http://www.cormedix.com

• General Corporate Information    Officers Joseph Todisco - Chief Executive Officer and Director Myron Kaplan - Chairman of the Board and Director Matthew David - Executive Vice President and Chief Financial Offic Janet Dillione - Director Gregory Duncan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 21900C308 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 67.82 Most Recent Split Date: 3.00 (0.20:1) Beta: 1.58 Market Capitalization: $794.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.96 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: 12.20 Trailing 12 Months: 53.23 PEG Ratio: - Price Ratios Price/Book: 6.91 Price/Cash Flow: - Price / Sales: 9.62 EPS Growth vs. Year Ago Period: 220.00% vs. Previous Quarter: 36.36% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 25.23% ROE 06/30/25 - - 03/31/25 - 22.57 12/31/24 - -28.97 ROA 06/30/25 - - 03/31/25 - 17.02 12/31/24 - -22.26 Current Ratio 06/30/25 - - 03/31/25 - 4.21 12/31/24 - 3.39 Quick Ratio 06/30/25 - - 03/31/25 - 3.99 12/31/24 - 3.16 Operating Margin 06/30/25 - - 03/31/25 - 20.81 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - 20.81 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 20.81 12/31/24 - -44.45 Book Value 06/30/25 - - 03/31/25 - 1.69 12/31/24 - 1.40 Inventory Turnover 06/30/25 - - 03/31/25 - 0.62 12/31/24 - 0.62 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©